Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients with Advanced Solid Tumors
A Randomized Phase II Study of Erdafitinib Versus Investigator Choice of Intravesicular Chemotherapy in Subjects Who Received Bacillus Calmette-Gu�rin BCG and Progressed or Recurred With High Risk Non-Muscle-Invasive Bladder Cancer NMIBC and FGFR Mutations or Fusions
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Study Type: Treatment
Phase: I/II
NCTID: NCT06287775
Principal Investigator:
Chao Huang
Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
A Phase II, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
Study Type: Treatment
Phase: III
NCTID: NCT05838716
Principal Investigator:
Elizabeth Wulff-Burchfield
A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib LY3527723 in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy Lung-MAP Sub-Study NCT 05364645
A Phase II Study of Amivantamab SC subcutaneous in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer Lung-MAP Sub-Study?
Study Type: Treatment
Phase: II
NCTID: NCT06116682
Principal Investigator:
Chao Huang